BHVN - NYSE
Biohaven Ltd.
$10.81
+6.7%Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
At a Glance
Live SnapshotBiohaven Ltd. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Biohaven Ltd. Cash Flow Statement
BHVN • NYSE
| Biohaven Ltd. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-738.8M | -846.4M | -408.2M | -570.3M | -213.8M | -118.7M | -528.8M | -240.9M | -127.2M | |
9.9M | 7.9M | 6.9M | 1.4M | 1.4M | 72K | 0.0 | 0.0 | 0.0 | |
112.4M | 72M | 28.8M | 193.6M | 65.6M | 29.5M | 55M | 16.9M | 13.2M | |
5.7M | 167.3M | 16.1M | 106.3M | -740K | 4.2M | 93.2M | 21.5M | 15.2M | |
(0.0) | (0.0) | (0.0) | (38.2M) | (16.6M) | (2.8M) | (0.0) | (0.0) | (0.0) | |
1.4M | 16.8M | 24.6M | -28.6M | 1.7M | 9M | 3.3M | 5.4M | 4M | |
-609.4M | -582.5M | -331.7M | -297.7M | -145.8M | -76M | -377.3M | -197.1M | -94.8M | |
INVESTING ACTIVITIES | |||||||||
-715K | -4M | -3M | -41.1M | -938K | -2.7M | -2.5M | -4.2M | -541K | |
(0.0) | (391K) | (0.0) | (0.0) | (1.9M) | (0.0) | (0.0) | (0.0) | (0.0) | |
-266.9M | -745.7M | -194.1M | -263.7M | (0.0) | (0.0) | (0.0) | -6.4M | -6.6M | |
570M | 504.4M | 327M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.3M | 0.0 | 127K | |
(300.6M) | -245M | (129.8M) | -304.8M | (944K) | -2.7M | -3.8M | -10.5M | -7M | |
FINANCING ACTIVITIES | |||||||||
189.3M | 675.5M | 243.2M | 283.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
250M | 0.0 | 0.0 | 449.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-194K | 2.3M | -31.3M | 34.7M | 138.4M | 152.2M | 434.6M | 340.5M | 209.8M | |
439.1M | 677.8M | 211.9M | 767.6M | 138.4M | 152.2M | 434.6M | 340.5M | 209.8M | |
CASH FLOW SUMMARY | |||||||||
-3K | 75K | -497K | 429K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
130.2M | -149.6M | 9.5M | 165.5M | -6.4M | 73.6M | 53.5M | 132.8M | 107.9M | |
102.5M | 252.1M | 242.6M | 77.1M | 83.5M | 9.9M | 264.2M | 131.5M | 23.6M | |
232.8M | 102.5M | 252.1M | 242.6M | 77.1M | 83.5M | 317.7M | 264.2M | 131.5M | |
-610.2M | -586.5M | -334.8M | -338.8M | -146.8M | -78.7M | -379.9M | -201.3M | -95.4M |
SEC Filings
BHVN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 27, 2026 | May 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 04, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | April 28, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | March 13, 2026 | April 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 06, 2026 | 2026 |
Related Guides
Continue your BHVN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.